Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

Pulmonary fibrosis in patients with COVID-19 tends to resolve, while idiopathic pulmonary fibrosis always progresses.

Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it.

A novel once-daily drug showed a comparable efficacy and safety profile as the standard-of-care drug in patients with cystic ...

"Glox to develop precision antibiotics for cystic fibrosis" was originally created and published by Pharmaceutical Technology ...

Bryan Freedman, now defending his client against Blake Lively’s accusations over 'It Ends With Us,' claimed Baldoni’s ...

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

Idiopathic Pulmonary Fibrosis (IPF) is a chronic interstitial lung disease characterized by progressive scarring of lung ...

Virtual choir program founder Ashley Ballou-Bonnema shares her selfless story on living with and advocating for a life with the chronic disease.

DERMOT Bannon has said the kindness of strangers who helped build a home for charity will live with him “for the rest of his ...